US6821984B2 - Ring fused pyrazole derivatives as CRF antagonists - Google Patents

Ring fused pyrazole derivatives as CRF antagonists Download PDF

Info

Publication number
US6821984B2
US6821984B2 US10/308,386 US30838602A US6821984B2 US 6821984 B2 US6821984 B2 US 6821984B2 US 30838602 A US30838602 A US 30838602A US 6821984 B2 US6821984 B2 US 6821984B2
Authority
US
United States
Prior art keywords
alkyl
group
independently selected
hydrogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/308,386
Other languages
English (en)
Other versions
US20040006066A1 (en
Inventor
David Garrett Loughhead
Counde O'Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Priority to US10/308,386 priority Critical patent/US6821984B2/en
Assigned to SYNTEX (U.S.A.) LLC reassignment SYNTEX (U.S.A.) LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOUGHHEAD, DAVID GARRETT, O'YANG, COUNDE
Publication of US20040006066A1 publication Critical patent/US20040006066A1/en
Priority to US10/914,368 priority patent/US7053103B2/en
Application granted granted Critical
Publication of US6821984B2 publication Critical patent/US6821984B2/en
Priority to US11/348,036 priority patent/US7268146B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
US10/308,386 2001-12-04 2002-12-03 Ring fused pyrazole derivatives as CRF antagonists Expired - Fee Related US6821984B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/308,386 US6821984B2 (en) 2001-12-04 2002-12-03 Ring fused pyrazole derivatives as CRF antagonists
US10/914,368 US7053103B2 (en) 2001-12-04 2004-08-09 Ring fused pyrazole derivatives as CRF antagonists
US11/348,036 US7268146B2 (en) 2001-12-04 2006-02-06 Ring fused pyrazole derivatives as CRF antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33675101P 2001-12-04 2001-12-04
US40861302P 2002-09-06 2002-09-06
US10/308,386 US6821984B2 (en) 2001-12-04 2002-12-03 Ring fused pyrazole derivatives as CRF antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/914,368 Division US7053103B2 (en) 2001-12-04 2004-08-09 Ring fused pyrazole derivatives as CRF antagonists

Publications (2)

Publication Number Publication Date
US20040006066A1 US20040006066A1 (en) 2004-01-08
US6821984B2 true US6821984B2 (en) 2004-11-23

Family

ID=26990355

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/308,386 Expired - Fee Related US6821984B2 (en) 2001-12-04 2002-12-03 Ring fused pyrazole derivatives as CRF antagonists
US10/914,368 Expired - Fee Related US7053103B2 (en) 2001-12-04 2004-08-09 Ring fused pyrazole derivatives as CRF antagonists
US11/348,036 Expired - Fee Related US7268146B2 (en) 2001-12-04 2006-02-06 Ring fused pyrazole derivatives as CRF antagonists

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/914,368 Expired - Fee Related US7053103B2 (en) 2001-12-04 2004-08-09 Ring fused pyrazole derivatives as CRF antagonists
US11/348,036 Expired - Fee Related US7268146B2 (en) 2001-12-04 2006-02-06 Ring fused pyrazole derivatives as CRF antagonists

Country Status (16)

Country Link
US (3) US6821984B2 (de)
EP (1) EP1453832B1 (de)
JP (1) JP4290555B2 (de)
KR (1) KR100760072B1 (de)
CN (1) CN1326855C (de)
AR (1) AR037694A1 (de)
AT (1) ATE335740T1 (de)
AU (1) AU2002356725B2 (de)
BR (1) BR0214695A (de)
CA (1) CA2468927A1 (de)
DE (1) DE60213851T2 (de)
ES (1) ES2269822T3 (de)
MX (1) MXPA04005426A (de)
PL (1) PL371049A1 (de)
RU (1) RU2318822C2 (de)
WO (1) WO2003048160A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197330A1 (en) * 2004-02-18 2005-09-08 Roche Palo Alto Llc Heterocyclic GABAA subtype selective receptor modulators
US20060135555A1 (en) * 2001-12-04 2006-06-22 Roche Palo Alto Llc Ring fused pyrazole derivatives as CRF antagonists

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE10311300A1 (de) * 2003-03-14 2004-09-23 Bayer Cropscience Ag 2,4,6-Phenylsubstituierte cyclische Ketoenole
WO2006044821A1 (en) * 2004-10-19 2006-04-27 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
AU2006264170A1 (en) * 2005-06-27 2007-01-04 Ambrilia Biopharma Inc. Pyrazolo[3,4-b]pyridin-2-yl)-benzoic acid derivatives as HIV integrase inhibitors
WO2007115966A1 (en) * 2006-04-11 2007-10-18 F. Hoffmann-La Roche Ag Heterocyclic gaba alpha subtype selective receptor modulators
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP3239170B1 (de) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
WO2014094357A1 (en) * 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN114805347B (zh) * 2022-05-12 2023-10-20 贵州大学 一种有机催化合成手性吡唑并[3,4-b]吡啶酮类化合物及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668145A (en) 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
US5705646A (en) 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5712303A (en) 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US6200979B1 (en) 1994-06-15 2001-03-13 Gene M. Bright Methods of administering CRF antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056611C (zh) * 1994-06-16 2000-09-20 美国辉瑞有限公司 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
FR2741072B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique
DE60213851T2 (de) * 2001-12-04 2007-09-13 F. Hoffmann-La Roche Ag Ringannelierte pyrazolderivate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712303A (en) 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US5705646A (en) 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
US6200979B1 (en) 1994-06-15 2001-03-13 Gene M. Bright Methods of administering CRF antagonists
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Ambinter, Paris, France, Database Chemcats online! Chemical Abstracts Service, Columbus, Ohio, US; retrieved from STN XP-002233226, Order Nos.: 132-45219; 132-45159; 132-45157; 132-45155; Stock1S-39093, Stock1S-34168; dated Jan. 21, 2002.
Asinex, Moscow, Russia, Database Chemcats online! Chemical Abstracts Service, Columbus, Ohio, US; retrieved from STN XP-002233224, Order No.: BAS 0138479, dated May 10, 2001.
Caplus ,English Abstract AN 1981:550528 Synthesis of pyrazolotetrahydropyridinones . . . 1981 21(7) pp. 259-260.* *
ChemStar Ltd, Moscow, Russia, Database Chemcats online! Chemical Abstracts Service, Columbus, Ohio, US; retrieved from STN XP-002233223, Order Nos.: CHS 0390519; CHS 0053761, dated May 16, 2001.
Hehemann, et al., "Addition of Diamines to Methylthiopyridones," J. Heterocyclic Chem., (1994), pp. 393-396, vol. 31 (2).
Mohareb, et al., "Reactions with 4-Phenyl-3-thiosemicarbazide: A New Approach for the Synthesis of Pyrazole, Thiazole, Pyridine and Pyrazolo[3,4-b]-Pyridine Derivatives," Sulfur Letters, (1991), pp. 101-113, vol. 13 (3).
Specs and Biospecs B.V., Rijswijk, NL, Database Chemcals online! Chemical Abstracts Service, Columbus, Ohio, US; retrieved from STN XP-002233225, Order No.: AG-667/12449002 & "Compounds for Screening", dated Jul. 1, 2001.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135555A1 (en) * 2001-12-04 2006-06-22 Roche Palo Alto Llc Ring fused pyrazole derivatives as CRF antagonists
US7268146B2 (en) * 2001-12-04 2007-09-11 Palo Alto Llc Ring fused pyrazole derivatives as CRF antagonists
US20050197330A1 (en) * 2004-02-18 2005-09-08 Roche Palo Alto Llc Heterocyclic GABAA subtype selective receptor modulators
US7432283B2 (en) * 2004-02-18 2008-10-07 Roche Palo Alto Llc Heterocyclic GABAA subtype selective receptor modulators

Also Published As

Publication number Publication date
CA2468927A1 (en) 2003-06-12
US20040006066A1 (en) 2004-01-08
AU2002356725B2 (en) 2008-07-17
CN1326855C (zh) 2007-07-18
US7268146B2 (en) 2007-09-11
EP1453832A1 (de) 2004-09-08
MXPA04005426A (es) 2004-10-11
KR20050044652A (ko) 2005-05-12
RU2004120773A (ru) 2005-05-27
KR100760072B1 (ko) 2007-09-18
JP4290555B2 (ja) 2009-07-08
AU2002356725A1 (en) 2003-06-17
PL371049A1 (en) 2005-06-13
DE60213851T2 (de) 2007-09-13
ATE335740T1 (de) 2006-09-15
BR0214695A (pt) 2004-11-03
EP1453832B1 (de) 2006-08-09
ES2269822T3 (es) 2007-04-01
JP2005517644A (ja) 2005-06-16
US7053103B2 (en) 2006-05-30
RU2318822C2 (ru) 2008-03-10
US20060135555A1 (en) 2006-06-22
US20050014781A1 (en) 2005-01-20
CN1599737A (zh) 2005-03-23
WO2003048160A1 (en) 2003-06-12
AR037694A1 (es) 2004-12-01
DE60213851D1 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
US7268146B2 (en) Ring fused pyrazole derivatives as CRF antagonists
JP4031363B2 (ja) α−１Ａ／Ｂアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
US20070213373A1 (en) Indazole derivatives as CRF antagonists
US7365211B2 (en) Heterocyclic GABAA subtype selective receptor modulators
US7432283B2 (en) Heterocyclic GABAA subtype selective receptor modulators
US7091200B2 (en) Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
AU665137B2 (en) 9H-imidazo(1,2-a)benzimidazole-3-acetamide derivates, their preparation and their therapeutic application
US5599812A (en) Tricyclic pyrrolopyrazine 5-HT3 -active compounds
MXPA06009179A (es) Moduladores de receptores selectivos del subtipo gaba-a heterociclicos

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYNTEX (U.S.A.) LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOUGHHEAD, DAVID GARRETT;O'YANG, COUNDE;REEL/FRAME:013428/0329

Effective date: 20021126

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20121123